Latest Industry Insights
Industry Insight
Therapeutically Targeting DYRK1A in Alzheimer’s Disease
Alzheimer’s disease (AD) is a neurodegenerative condition. There are currently no FDA-approved disease‐modifying therapies for AD, despite it being the most common cause of dementia. We recently spoke with Samumed’s CEO Osman Kibar, to learn more about the company's efforts to therapeutically target "DYRK1A" in AD.
Industry Insight
Simple Eye Measurement Helps Improve Outcomes for Brain Injury Patients
Pupillometry is an ingenious way of assessing brain health by measuring data from patients’ eyes. New technology has helped standardize pupillometry, and these measurements are now helping treat patients with life-threatening brain injuries. We spoke to Kathleen Pierson, Vice President, Global Sales and Marketing, at pupillometry leader NeurOptics, to find out more.
Industry Insight
The Way Forward for Antibodies in Neuroscience
Antibodies are an essential part of everyday neuroscience research. But recently, high-profile criticism has cast doubt on their reliability and reproducibility. We caught up with Bio-Techne’s Raymond Chan and Katherine Bradley to find out how providers are hoping to improve antibodies and make them fit for a more reproducible future in neuroscience.
Industry Insight
Entering the Antibody Lottery: Tips for Avoiding Dubious Sources
Having reliable antibodies can make or break your assay. However, sourcing the right antibody for the job can sometimes feel like you’re entering the lottery: there are so many on the market, and often they just don’t live up to what was promised. To learn more about antibody validation and its importance, we got in touch with Anthony Couvillon, PhD, Scientific Marketing Project Manager at Cell Signaling Technology.
Industry Insight
Take a Good Book Around
Our recent social media poll on "book recommendations for scientists" provided an incredible response. We decided to collate this information and give you the perfect excuse to treat yourself to a new read. Enjoy!
Industry Insight
The Vision for Multi-organ Human-on-a-Chip Models
The development of organ-on-a-chip models aims to reduce the (expensive) high drug failure rates that exist in clinical trials. A Florida biotech firm recently reported that their multi-organ “human-on-a-chip” system maintains cellular viability over 28 days in serum-free conditions, using a pumpless system. To learn more about the vision for multi-organ “human-on-a-chip” models, we caught up with James Hickman, Chief Science Officer of Hesperos Inc.
Industry Insight
The Booming Business of Neurotoxin Therapy
Botulinum neurotoxins are widely used in both therapeutic and cosmetic applications, but Ipsen says that their new rBoNT-E toxin is a step up from compounds based on the much more widely used serotype A toxin. We spoke to Ipsen Senior Vice President Neurosciences R&D, Philippe Picaut, to find out more.
Industry Insight
Harnessing AI in a Battle Against Aging
A recently announced collaboration between Juvenescence, Ltd., and NetraMark Corp. has yielded a new joint venture, NetraPharma, which aims to fight aging-related conditions. We spoke with NetraMark founder Dr. Joseph Geraci to find out more about how the process of targeting and treating neurodegenerative disorders will be radically changed by AI.
Industry Insight
Can We Treat Mood Disorders with Pharmacological Therapeutics?
Clinical treatments for neurological and mood disorders like social anxiety disorder and major depressive disorder have failed to show consistent efficacy in treating patients. VistaGen Therapeutics is aiming to correct that. We talked to VistaGen’s CEO, Shawn Singh, about the need for treatments in this area and why Vistagen thinks their compounds AV-101 and PH94B could be promising therapies.
Industry Insight
Brain Injury Diagnosed With Single Drop of Blood: a Follow-up
What do biomarkers and a 1990s TGIF party have in common? Find out here...
TBIcheck is a rapid point-of-care diagnostic device that detects biomarkers indicative of mild traumatic brain injury. To find out more, we spoke with the head of the Biomedical Proteomics Group, Jean-Charles Sanchez.
TBIcheck is a rapid point-of-care diagnostic device that detects biomarkers indicative of mild traumatic brain injury. To find out more, we spoke with the head of the Biomedical Proteomics Group, Jean-Charles Sanchez.
Advertisement